Low-level aviremic hepatitis C virus (HCV) RNA replication in the immune blood РBMСs/WBCs as one of the primary interferon-free DAA therapy outcomes in real clinical practice in antiviral therapy-naive patients with chronic HCV RNA viremia

DOI: https://doi.org/10.29296/25877305-2020-02-13
Download full text PDF
Issue: 
2
Year: 
2020

Professor A. Yakovlev(1, 2), MD; Professor D. Sulima(3, 4), MD; V. Larionov(5); V. Koryagin(4), Candidate of Medical Sciences; M. Sharipova(4), Candidate of Medical Sciences(4); I. Fedunyak(2, 6), Candidate of Medical Sciences; V. Musatov(1, 2), Candidate of Medical Sciences; G. Kachenya(2); Е. Doguzhneva(2); O. Sokolova(1, 2), Candidate of Medical Sciences; O. Gorchakova(3), Candidate of Medical Sciences; Professor A. Semenov(6, 7), BD; E. Zueva(7), Candidate of Biological Sciences; Yu. Ostankova(7), Candidate of Biological Sciences; S. Prosvernitsyn(4, 6), Candidate of Medical Sciences; S. Kiyashko(4, 5), Candidate of Medical Sciences; Yu. Chornoguz(7); D. Valutite(7) (1)Saint Petersburg State University (2)S.P. Botkin Clinical Infectious Diseases Hospital, Saint Petersburg (3)Acad. I.P. Pavlov First Saint Petersburg State Medical University (4)OOO «Exclusive» Medical Consulting Dental Center, Saint Petersburg (5)V.A. Almazov Medical Research Center, Saint Petersburg (6)I.I. Mechnikov North-Western State Medical University, Saint Petersburg (7)Research Institute of Epidemiology and Microbiology, Saint Petersburg

The paper presents the results of the authors’ own pilot study of the prevalence of secondary occult hepatitis C virus (HCV) infection after various primary interferon-free (direct-acting antivirals (DAA)) therapy regimens with original inhibitor drugs in real clinical practice. Examinations have been made in 27 patients randomly selected from 261 ones who achieved a traditional plasma sustained virological response at 12 weeks after the end of a DAA therapy cycle confirmed by HCV RNA aviremia.

Keywords: 
гепатология
вторичная оккультная HCV-инфекция
вторичный оккультный гепатит С
безинтерфероновая DAA-терапия
иммунные клетки крови PBMC/WBC
периферические мононуклеары
хроническая виремия RNA HCV
репликация RNA HCV в PBMC/WBC



It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Ferri C., Ramos-Casals M., Zignego A.L. et al. International diagnostic guidelinesforpatients with HCV- expertstatement // Autoimmun. Rev. – 2016; 15 (12): 1145–60. DOI: 10.1016/j.autrev.2016.09.006
  2. McHutchinson J., Davis G., Esteban-Mur R. et al. Durability of sustainedviralresponse in patients with chronic hepatitis C aftertreatment with interferon alpha-2b aloneor in combination with ribavirin // Hepatology. – 2001; 34: 244.
  3. Shiratori Y., Imazeki F., Moriyama M. et al. Histologicimprovement of fibrosis in patients with hepatitis C whohavesustainedresponse to interferon therapy // Ann. Intern. Med. – 2000; 132: 517–24.
  4. Castillo I., Pardo M., Bartolomé J. et al. Occult Hepatitis C Virus Infection in Patients in Whom the Etiology of PersistentlyAbnormal Results of Liver-Function Tests Is Unknown // J. Infect. Dis. – 2004; 189 (1): 7–14.
  5. Attar V., VanThiel D. Review Article. A New Twist to a Chronic HCV Infection: Occult Hepatitis C // Gastroenterol. Res. Pract. – 2015; 2015: 579147. http://dx.doi.org/10.1155/2015/579147
  6. AbdAlla M., ElAwady M. Hepatitis C virus RNA strands detection in peripheral blood mononuclear cells legitimizes virus eradication in negative serumpcrnaive and post-treatment patients // J. Clin. Transl. Hepatol. – 2017; 5 (1): 1–8. DOI: 10.14218/JCTH.2016.00054
  7. Innes H., McDonald S., Hayes P. et al. Mortality in hepatitis C patients who achieve a sustained viral response compared to the general population // J. Hepatol. – 2017; 66 (1): 19–27. https://doi.org/10.1016/j.jhep.2016.08.004
  8. Yousif M., ElsadekFakhr A. et al. Prevalence of occult hepatitis C virus infection in patients who achieved sustained virologic response todirect-acting antiviral agents // Infez. Med. – 2018; 26 (3): 237–43.
  9. Mekky M., Sayed H., Abdelmalek M. et al. Prevalence and predictors of occult hepatitis C virus infection among Egyptian patients who achieved sustained virologic response to sofosbuvir/daclatasvir therapy: a multi centerstudy // Infect. Drug Resist. – 2019; 12: 273–9. DOI: 10.2147 / IDR.S181638
  10. Wróblewska A., Lorenc B., Cheba M. et al. Neutrocyte to lymphocyte ratiopredicts the presence of a replicative hepatitis C virus strand after therapy with direct acting antivirals // Clin. Exp. Med. – 2019; 19: 401–6. https://doi.org/10.1007/s10238-019-00561-y
  11. Lybecka C., Brenndörferc E., Sällbergc M. et al. Long-term follow-up aftercure from chronic hepatitis C virus infection shows occult hepatitis and a risk of hepatocellular carcinoma in noncirrhotic patients // Eur. J. Gastroenterol. Hepatol. – 2019; 31 (4): 506–13. DOI: 10.1097/MEG.0000000000001316
  12. Znojko O.O., Lin'kova Ju.N., Morozova M.A. i dr. Klinicheskij opyt primenenija shemy trojnoj terapii, vkljuchajuschej tsepeginterferon al'fa-2b, simeprevir i ribavirin, u patsientov s hronicheskim gepatitom S genotipa 1 // Infektsionnye bolezni: novosti, mnenija, obuchenie. – 2016; 2 (15): 100–9 [Znoyko O.O., Lin’kova Yu.N., Morozova M.A. et al. Clinical practice of triple therapy with Cepeginterferon alfa-2b, simeprevir and ribavirin in patients with chronic hepatitis C virus genotype 1 infection // Infektsionnye bolezni: novosti, mneniya, obuchenie. – 2016; 2 (15): 100–9. (in Russ.)].
  13. Sulima D.L., Lioznov D.A., Jakovlev A.A. i dr. Pervyj v Rossii opyt primenenija GLE/PIB dlja lechenija HCV-infektsii genotipa 3a s krioglobulinemiej i soputstvujuschej HBV-infektsiej u patsienta s HBP S5d, lechennogo gemodializom i ozhidavshego transplantatsiju pochki // Vrach. – 2019; 30 (2): 3–13 [Sulima D., Lioznov D., Yakovlev A. et al. Russia’s first experience with GLE/PIB for the treatment of HCV infection genotype 3A with cryoglobulinemia and concomitant HBV infection in a hemodialysis patient with CKD S5d awaiting kidney transplantation // Vrach. – 2019; 30 (2): 3–13 (in Russ.)]. https://doi.org/10.29296/25877305-2019-02-01
  14. Sulima D.L., Sokolova O.I., Larionov V.A. i dr. Bezinterferonovaja DAA-terapija u patsientov s hronicheskoj HCV-infektsiej (novaja gipoteza na osnovanii 3-letnego prospektivnogo nabljudatel'nogo issledovanija dvuh klinik Sankt-Peterburga) // Sovremennaja meditsina. – 2019; 3 (15): 7–29 [Sulima D.L., Sokolova O.I., Larionov V.A. et al. Interferon-free DAA-therapy in patients with chronic HCV infection (new hypothesis based on a 3-year prospective observational study of two clinics in St. Petersburg) // Sovremennaya meditsina. – 2019; 3 (15): 7–29 (in Russ.)].
  15. Chomczynski P., Sacchi N. // Single-stepmethod of RNA isolation by acid guanidinium thiocyanate-phenol-chloroformextraction // Anal. Biochem. – 1987; 162 (1): 156–9.
  16. EASL Recommendations on Treatment of Hepatitis C 2015 // J. Hepatol. – 2015; 63: 199–236. DOI: 10.1016/j.jhep.2015.03.025
  17. EASL Recommendations on Treatment of Hepatitis C 2016 // J. Hepatol. – 2017; 66: 153–94. https://doi.org/10.1016/j.jhep.2016.09.001
  18. EASL Recommendations on Treatment of Hepatitis C 2018 // J. Hepatol. – 2018; 69: 461–511. https://doi.org/10.1016/j.jhep.2018.03.026
  19. Prihod'ko E.M., Seliverstov P.V., Adylov Sh.F. i dr. Vozmozhnosti regenerativnoj terapii v lechenii patsientov s hronicheskim gepatitom // Gastroenterologija Sankt-Peterburga. – 2018; 2: 91–2 [Prikhod’ko E.M., Seliverstov P.V., Adylov Sh.F. et al. Vozmozhnosti regenerativnoi terapii v lechenii patsientov s khronicheskim gepatitom // Gastroenterologiya Sankt-Peterburga. – 2018; 2: 91–2 (in Russ.)].